Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now full pipeline small index

Oligometastatic Malignant Solid Neoplasm: full-pipeline trial registry

1 of 2 indexed Oligometastatic Malignant Solid Neoplasm trials are currently recruiting.

Corpus placement: #7,203 of 28,963 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,203 of 28,963 conditions by registered trial count

Oligometastatic Malignant Solid Neoplasm: 2 US clinical trials tracked, 1 recruiting.

Oligometastatic Malignant Solid Neoplasm is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 1 of these trials.

Open enrollment snapshot

Oligometastatic Malignant Solid Neoplasm has 2 registered US clinical trials, 1 of them open to new participants right now, about 50% of the total.

1
recruiting participants now
50%
of trials open to enrollment
1
in Phase 3-4 (later-stage)
1
top sponsor: M.D. Anderson Cancer Center

Corpus placement: #7,203 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Oligometastatic Malignant Solid Neoplasm on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Oligometastatic Malignant Solid Neoplasm is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 28,061 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21Phase 31

What is open for Oligometastatic Malignant Solid Neoplasm right now

1 recruiting of 2 indexed (50% open).

Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).

Top sponsor: M.D. Anderson Cancer Center (1 trial), 1 other listed. 2 shown below, recruiting first. #7,203 of 28,963 conditions by registered trial count.

Why a small condition index still matters

Thin indexes still surface the registry rows that exist for this label. Counts stay small when ClinicalTrials.gov lists few studies under the condition string, not because this page omits rows. Verify any enrollment decision on ClinicalTrials.gov and with a clinician.

Frequently Asked Questions

How many clinical trials are there for Oligometastatic Malignant Solid Neoplasm?

PlainTrial tracks 2 US clinical trials for Oligometastatic Malignant Solid Neoplasm, of which 1 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Oligometastatic Malignant Solid Neoplasm?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.